Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab maintenance after chemoradiotherapy for unresected locally advanced head and neck squamous cell carcinoma
MOH_2024-06-28_013494Phase 3Recruiting
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Dostarlimab with Placebo (2 arms). Started May 2024; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2024-06-28_013494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-06-28_013494.